ALTERNATING DRUG-COMBINATIONS IN THE TREATMENT OF ADVANCED HODGKINS-DISEASE
ALTERNATING DRUG-COMBINATIONS IN THE TREATMENT OF ADVANCED HODGKINS-DISEASE
复制标题
DOI：
10.1056/nejm198204013061303
复制
发表时间：
1982-01-01
影响因子：
158.5
通讯作者：
VALAGUSSA, P
中科院分区：
文献类型：
--
作者：
SANTORO, A;BONADONNA, G;VALAGUSSA, P
在75例连续的IV期霍奇金病患者中，38例被分配单独接受MOPP（甲氯他明、长春新碱、丙卡嗪和强的松），37例被分配每月交替接受MOPP和ABVD（阿霉素、博来霉素、长春碱和卡帕嗪），这是一种与MOPP无交叉耐药的药物组合。单独接受MOPP治疗的患者有71%完全缓解，而接受交替治疗的患者有92%完全缓解（P = 0.02）。5年时，37%的MOPP组和70%的MOPP + abvd组没有疾病进展（P < 0.0001）。化疗后，MOPP组的中位无复发生存期为20个月，MOPP + abvd组的中位无复发生存期超过31个月（P < 0.01）。在接受MOPP和ABVD治疗的患者中，无疾病证据的5年生存率为84%，而单独接受MOPP治疗的患者为54% （P < 0.005）。交替的非交叉耐药组合在晚期霍奇金病的治疗中显得很有希望，并且值得在其他恶性疾病中进行试验。
Of 75 consecutive patients with Stage IV Hodgkin''s disease, 38 were assigned to receive MOPP alone (mechlorethamine, vincristine, procarbazine and prednisone) and 37 to receive MOPP alternating monthly with ABVD (doxorubicin, bleomycin, vinblastine and carbazine), a combination of drugs not cross-resistant with MOPP. Complete remission was documented in 71% of the patients receiving MOPP alone and in 92% of those receiving the alternating regimen (P = 0.02). At 5 yr, there was no progression of disease in 37% of the MOPP group and in 70% of the MOPP-plus-ABVD group (P < 0.0001). After chemotherapy, the median relapse-free survival period was 20 mo. in the MOPP group and over 31 mo. in the MOPP-plus-ABVD group (P < 0.01). Five yr survival with no evidence of disease was 84% in patients given MOPP and ABVD and 54% in those given MOPP alone (P < 0.005). Alternating non-cross-resistant combinations appear promising in the management of advanced Hodgkin''s disease and are worthy of trial in other malignant diseases.